Research Article

Loss of ABCB4 attenuates the caspase-dependent apoptosis regulating resistance to 5-Fu in colorectal cancer

Hangqiing Hu¹, Meng Wang¹, Xu Guan², Ziming Yuan¹, Zheng Liu², Chaoxiao Zou³, Guiyu Wang¹, Xu Gao³ and Xishan Wang¹,²

¹Department of Colorectal Surgery, the Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China; ²Department of Colorectal Surgery, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China; ³Department of Biochemistry and Molecular Biology, Harbin Medical University, Harbin, Heilongjiang, China

Correspondence: Xu Gao (gaoxu6712@163.com) or Xishan Wang (wxshan1208@126.com)

The adenosine triphosphate-binding cassette (ABC) is a large group of proteins involved in material transportation, cellular homeostasis, and closely associated with chemoresistance. ATP-binding cassette protein B4 (ABCB4) is a member of ABCs which has a similar structure to ABCB1, but fewer researches were performed. The present study is aimed to investigate the putative mechanism of ABCB4 in 5-fluorouracil (5-Fu) resistance. Then, we found that ABCB4 was significantly down-regulated in the 5-Fu resistant HCT8 cell lines by polymerase chain reaction (PCR) and Western blot. The knockdown of ABCB4 by small interfering RNA decreased the apoptosis by 5-Fu in resistant HCT8R cell lines without influencing the proliferation. Also, we found a lower expression of cleaved caspase and PARP by Western blot after the knockdown of ABCB4. However, the knockdown of ABCB4 did not influence the proliferation and apoptosis. Furthermore, the histological detection of ABCB4 mRNA level in human colorectal cancer tissues and even in the recurrent tissues after 5-Fu single-agent chemotherapy was employed to provide more concrete evidence that ABCB4 may be a tumor suppressor gene to regulate chemoresistance in colorectal cancer. Moreover, a 109-patient cohort revealed that ABCB4 predicted a poor recurrence-free survival and overall survival. In summary, ABCB4 was down-regulated in the 5-Fu resistant cells and knockdown of ABCB4 alleviated the cell apoptosis and predicts a shorter recurrence-free survival and overall survival.

Introduction

The colorectal cancer (CRC) is a major cause of cancer-related mortality [1]. It arises from the accumulation of a serial genetic mutation in the normal epithelium, ranging from the development of adenoma to cancer [2]. The adjuvant therapeutic modalities such as radiotherapy and chemotherapy are applied to eliminate the residual cancer cells after surgery, but their efficiency is limited by the recurrence resulted from the resistance to the drugs.

The 5-fluorouracil (5-Fu) is a cornerstone of systemic chemotherapy for treatment of colorectal cancer [3,4]. It brings about the cytotoxicity by inhibiting the thymidylate synthase as well as incorporating fluoronucleotides into RNA and DNA [5]. It has been reported that some CRC patients are primarily resistant to 5-Fu based chemotherapy and some will acquire the resistance after chemotherapy. Thus, it is necessary to reveal the potential targets for treatment of CRC patients with 5-Fu resistance.

ABC transporters, a large group of protein membrane complexes, divided into seven subclasses ranging from ABC-A to ABC-G [6]. Such a superfamily plays an important role in the resistance of cancer. Multidrug resistance protein 1 (MDR1), also known as P-glycoprotein (P-gp) or ABCB1, functions...
as a wide-spectrum therapeutic resistant factor by drug efflux [7-9]. The ATP-binding cassette protein C2 (ABCC2) modulates the resistance to cisplatin, methotrexate, doxorubicin, mitoxantrone, and etoposide [10-13]. The other member, ABCC2, is expressed in the apical surface of proximal tubule cells such as enterocytes and hepatocytes [14,15], contributing to the distribution and elimination of many drugs [8,9].

The ABCC4 was found to locate on the canalicular membrane of hepatocytes secreting phosphatidylcholine into bile to protect the hepatobiliary epithelium from damage of free bile acids and defects of ABCC4 cause rare biliary diseases [16-19]. ABCC4 shares similarities with ABCB1/MDR1, another member of ABC protein superfamily, in amino acid sequences [20]. Both members are polytopic transmembrane glycoproteins with two transmembrane modules each spanning the membrane six times and two ATP-binding domains [21]. However, the involvement of ABCC4 in colorectal cancer resistance remains to be illustrated.

In the present study, we found lower expression of ABCC4 in the 5-Fu resistant HCT8 colon cancer cell lines (HCT8R) than the corresponding 5-Fu sensitive HCT8 cells (HCT8S). And then, we validated a hypothesis that the loss of ABCC4 enhanced the resistance to 5-Fu via inhibiting apoptosis. Besides, ABCC4 was down-regulated in the primary tumor tissues and recurrent tissues. Furthermore, low expression of ABCC4 predicted a poor survival. ABCC4 may serve as a clinical marker in colorectal cancer patients.

**Methods**

**Cell culture**

Human CRC HCT8S and HCT8R were purchased from Shanghai Meixuan Corporation (Shanghai, China). HCT8S cell lines were cultured in Dulbecco’s Modified Eagle’s medium (GIBCO, Carlsbad, CA, U.S.A.) supplemented with 10% fetal bovine serum (GIBCO, Carlsbad, CA, U.S.A.). HCT8R cell lines were cultured in RPMI 1640 medium (GIBCO, Carlsbad, CA, U.S.A.) with 10% fetal bovine serum and 15 μg/ml 5-Fu (Sigma-Aldrich, Northbrook, IL, U.S.A.) according to the manufacturer’s protocols. Both kinds of cells were maintained in an atmosphere containing 5% CO₂ at 37°C according to a previous report [22].

**Colony formation and cell proliferation assay**

The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was performed to detect the cell proliferation according to a study previously reported [23]. Cells were plated in six-well plates at 500 cells per well in 2 ml of complete media. At the end-point, cells were stained with 0.1% Crystal Violet and number of colonies was counted.

**Flow cytometry**

Apoptosis was examined by flow cytometric analysis. An Annexin V fluorescein isothiocyanate/propidium iodide (FITC/PI) double stain assay (BD Biosciences, San Jose, CA, U.S.A.) was performed following the manufacturer’s protocol. The analysis was performed with FlowJo software (Treestar,Inc., San Carlos, CA, U.S.A.). All the assays were performed in triplicate.

**Western blot**

Western blot was performed using standard techniques as described previously [24]. Total cell extracts were collected and quantified using BCA Protein Assay Kit (Wanlei Bio, Shenyang, China) according to the manufacturer’s protocols. Fifty micrograms of proteins were electrophoresed through 10% sodium dodecyl sulfate (SDS) polyacrylamide gels and then transferred onto polyvinylidene fluoride (PVDF) membranes (Millipore, U.S.A.). The membranes were blocked with 5% non-fat milk in TBST for 2 h at room temperature and incubated with primary antibodies overnight at 4°C. Secondary antibodies labeled with HRP were used to incubate the membrane at room temperature for 2 h and the signals were detected using ECL Kit (Wanlei Bio, Shenyang, China). Subsequently, the images were analyzed by ImageJ 1.43 software. A β-actin antibody was used as a control for the whole-cell lysates. Antibodies are listed as follows: β-actin (1:1000, Cell Signaling Technology, Danvers, MA, U.S.A.), ABCC4 (1:500, Abcam, Cambridge, MA, U.S.A.), cleaved caspase-3 (1:1000, Cell Signaling Technology, Danvers, MA, U.S.A.), caspase-3 (1:1000, Cell Signaling Technology, Danvers, MA, U.S.A.), PARP (1:1000, Cell Signaling Technology, Danvers, MA, U.S.A.), cleaved PARP (1:1000, Cell Signaling Technology, Danvers, MA, U.S.A.), and anti-Rabbit or anti-Mouse HRP antibody (1:10000, Cell Signaling Technology, Danvers, MA, U.S.A.).
RNA retraction and qRT-PCR
Total RNA was extracted from tissues and cells with TRizol reagent (Invitrogen, Carlsbad, CA, U.S.A.) according to manufacturer’s instructions. One microgram of total RNA was reverse-transcribed using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA, U.S.A.) according to the manufacturer’s instructions. DNA was quantified using Nanodrop 2000 spectrophotometer (Thermo Fisher Scientific, Waltham, MA, U.S.A.). One microliter of DNA (0.8 ng) was used in each 20 µl of mixes performed by 40 cycles on triplicate samples in a reaction mix of SYBR Green (Thermo Fisher Scientific, Waltham, MA, U.S.A.) with Applied Biosystem 7500 quantitative PCR system (Applied Biosystems, Foster City, CA, U.S.A.) as previously described [25]. The mRNA levels were normalized against β-actin and the final data was shown as −ΔΔCt according to the formula: −ΔΔCt = −[(Ct target gene − Ct house keeping gene)treatment − (Ct target gene − Ct house keeping gene)control]. Sequences of the primers are as following: ABCB4 forward primer, 5′-atagcttacggatcgctctc-3′; ABCB4 reverse primer: 5′-ggtttgaagccgctttcct-3′; β-actin forward primer, 5′-tgccacacgacaatgtg-3′; β-actin reverse primer, 5′-ctaatgcttctgccttacagca-3′.

Oligonucleotide transfection
siRNA was purchased from GenePharma (Shanghai, China). Oligonucleotide transfection was performed using the Lipofectamine 2000 transfection reagent (Thermo Fisher Scientific, Waltham, MA, U.S.A.) according to manufacturer’s instructions, while nonspecific siRNA was used as negative controls. The sequences of siRNAs were presented as following, siNC, sense: 5′‐uuuccagccaugucuaagutt-3′, anti-sense: 5′‐acgugacagcuugagaatt-3′. siABCB4, sense: 5′‐gccuaauaacagguuuucutt-3′, anti-sense: 5′‐augaauacuuguaauaggctt-3′.

Ectopic expression of ABCB4 and plasmid transfection
The empty vector plasmid and ABCB4 overexpression plasmid were synthesized and purchased from Genscript Corporation (Nanjing, China). Both the control and the ABCB4 overexpression plasmids were transfected using the Lipofectamine 3000 transfection reagent (Thermo Fisher Scientific, Waltham, MA, U.S.A.) according to the manufacturer’s protocol.

Patient samples
CRC tissues and corresponding normal tissues were obtained from 109 patients or 8 recurrent patients who received colectomy in the Department of Colorectal Cancer Surgery, the Second Affiliated Hospital of Harbin Medical University between March 2012 and March 2014. The samples were frozen immediately in liquid nitrogen. The recurrence was defined as progressive disease according to the Response Evaluation Criteria in Solid Tumors (RECIST) principles. All clinical samples were collected with written informed consents from patients in our department, and the ethical approval was granted from the Review Board of Hospital Ethics Committee, the Second Affiliated Hospital of Harbin Medical University.

Statistical analysis
Statistical analyses were carried out using GraphPad Prism, version 6.0 (GraphPad, La Jolla, CA, U.S.A.) or SPSS, version 23.0 (SPSS Inc, Chicago, IL, U.S.A.). Data from at least three independent experiments performed in triplicates are presented as the means ± SD. Error bars in the scatterplots and the bar graphs represent SD. Data were examined to determine whether they were normally distributed with the One-Sample Kolmogorov–Smirnov test. If the data were normally distributed, comparisons of measurement data between two groups were performed using independent sample t test and the comparisons among two groups. If not normally distributed, performed by nonparametric test. The difference of the survival of between different groups was carried out using the Log-rank test or COX regression. Statistical tests were two-tailed and a P value of less than 0.05 was considered statistically significant.

Results
ABCB4 is down-regulated in HCT8R cell lines
First of all, the resistance to 5-Fu in HCT8R was validated using MTT assay. The 50% inhibitory concentration (IC50) value was much higher in HCT8R cells compared with the HCT8S cells (50.17 ± 1.84 µg/ml vs 14.73 ± 2.64 µg/ml, P < 0.001) (Figure 1A). In order to explore ABC members involved in the mechanism of HCT8R cells, qRT-PCR was carried out to detect the expression of ABCs. Among the genes, ABCB4 was the most notably down-regulated in the HCT8 5-Fu resistant cells (Figure 1B). Furthermore, Western blot assay verified the down-regulation of ABCB4 in HCT8R cells (Figure 1C).
Knockdown of ABCB4 enhanced the resistance in HCT8S cells

Next, to determine the function of ABCB4 in HCT8S cells, we knocked down the ABCB4 expression by siRNA and the efficacy of knockdown was confirmed by Western blot (Figure 2D). Then, the hypothesis that ABCB4 regulates the chemoresistance in HCT8S cells was tested. Compared with the negative control, ABCB4-knockdown increased the chemoresistance in HCT8S cells (Figure 2A). But, the ABCB4-knockdown showed no impact on the cell proliferation (Figure 2A). Colony formation assay showed that ABCB4 depletion did not regulate the proliferation of cells, but enhanced the resistance to 5-Fu (Figure 2B). Additionally, depletion of ABCB4 decreased the cell apoptosis only in 5-Fu treatment group by flow cytometry (Figure 2C). Consistently, Western blot assay revealed reducing cleaved caspase-3 and cleaved PARP after ABCB4 knockdown with 5-Fu treatment (Figure 2D). Above all, these results suggest that suppression of ABCB4 enhances the resistance to 5-Fu through decreasing the cell apoptosis.

Ectopic expression of ABCB4 enhanced the sensitivity in HCT8R cells

To verify ABCB4 as a tumor suppressor, we ectopically expressed the ABCB4 in HCT8R cells (Figure 3D). Via MTT assay, ectopically expressed ABCB4 exhibited enhanced sensitivity to 5-Fu, but had no effect on proliferation without 5-Fu treatment (Figure 3A). Colony formation assay also confirmed that ABCB4 boosted the sensitivity to 5-Fu in HCT8R cells (Figure 3B). Besides, overexpression of ABCB4 induced the apoptosis caused by 5-Fu by flow cytometry (Figure 3C). Consistently, Western blot assay showed increasing cleaved caspase-3 and cleaved PARP caused by 5-Fu after ectopic expression of ABCB4 (Figure 3D). Taken together, these results imply that ABCB4 enhances sensitivity to 5-Fu via inducing apoptosis.

ABCB4 was down-regulated in the colorectal cancer patients and predicted a poor survival

To investigate potential clinical significance of ABCB4, we analyzed the expression of ABCB4 in normal and tumor tissues from the clinical patients. As expected, ABCB4 was significantly decreased in the tumor tissues of TCGA(COADREAD) Cohort (Figure 4A). A 109-patient CRC cohort (Cohort1) and 8-patitnet recurrent cohort (Cohort2) was selected from our department and the demographic characteristics were shown (Tables 1 and 2). Thus, we examined the expression of ABCB4 in eight recurrent patients after 5-Fu based single-agent chemotherapy by qRT-PCR. Compared with the p-tumor tissues, ABCB4 was significantly lower in the recurrent tumor tissues (Figure 4B). Next, we examined the putative clinical significance of ABCB4 in our cohort. Lower expression of ABCB4 predicted a shorter RFS (Figure 4C) and OS (Figure 4D). Univariate and multivariate COX regression analyses revealed that the expression of ABCB4 was an independent predictor of CRC aggressiveness (Table 3). Our data indicate that ABCB4 is pathologically and clinically associated with CRC recurrence and outcomes.

Discussion

The potential roles of ABC family members involved in the chemoresistance have been reported extensively [8-15]. Increasing evidences have shown ABCB4 plays a part in the cancer resistance and growth. A microarray-based study
Figure 2. Knockdown of ABCB4 decreases apoptosis to regulate the resistance in the HCT8S cells

(A) Knockdown of ABCB4 significantly increased the chemoresistance of HCT8S cells, but had no effect on the cell viability without 5-Fu treatment. Cell viability was detected by MTT assay. Data are mean ± SD from three independent experiments; ***P<0.001.

(B) The colony formation assay were performed with or without the treatment of 5-Fu after the knockdown of the ABCB4. (C) Cell apoptosis by flow cytometry analysis after Annexin V-FITC and PI double staining. Data are mean ± SD from three independent experiments; ***P<0.001. (D) The knockdown of ABCB4 was confirmed by Western Blot. Apoptosis-related proteins were detected by Western Blot with or without 5-Fu treatment.

Table 1 Demographic characteristics of the patients in Cohort1

| Variables                      | High-expression (n=55) | Low-expression (n=54) | P     |
|--------------------------------|------------------------|-----------------------|-------|
| Age                            | 62.35 ± 14.32          | 62.91 ± 13.55         | 0.834 |
| Gender                         |                        |                       | 0.389 |
| Male                           | 30(54.5%)              | 25(46.3%)             |       |
| Female                         | 25(45.5%)              | 29(53.7%)             |       |
| TNM Stage                      |                        |                       | 0.367 |
| Early stage(stage I + stage II)| 31(56.4%)              | 35(64.8%)             |       |
| Late stage(stage III + stage IV)| 24(43.6%)             | 19(35.2%)             |       |
| Perineural invasion            |                        |                       | 0.19  |
| YES                            | 24(43.6%)              | 17(31.5%)             |       |
| NO                             | 31(56.4%)              | 37(68.5%)             |       |
| Lymphatic invasion             |                        |                       | 0.884 |
| YES                            | 17(30.9%)              | 16(29.6%)             |       |
| NO                             | 38(69.1%)              | 38(70.4%)             |       |
| Venous invasion                |                        |                       | 0.254 |
| YES                            | 19(34.5%)              | 13(24.5%)             |       |
| NO                             | 36(65.5%)              | 41(75.5%)             |       |
Figure 3. Overexpression of ABCB4 induces apoptosis to regulate the sensitivity in the HCT8R cells

(A) Overexpression of ABCB4 significantly increased the sensitivity of HCT8R cells. Cell viability was detected by MTT assay. Data are mean ± SD from three independent experiments; *P<0.05. (B) The colony formation assay were performed with or without the treatment of 5-Fu after the overexpression of the ABCB4. (C) Cell apoptosis by flow cytometry analysis after Annexin V-FITC and PI double staining. Data are mean ± SD from three independent experiments; **P<0.01.***P<0.001. (D) The overexpression of ABCB4 was confirmed by Western Blot. Apoptosis-related proteins were detected by Western Blot with or without 5-Fu treatment.

Table 2 Demographic characteristics of the patients in Cohort2

| Case   | Age | Gender | TNM Stage | Primary tumor site | Perineural invasion | Lymphatic invasion | Venous invasion | regime          | RFS (months) |
|--------|-----|--------|-----------|-------------------|---------------------|-------------------|----------------|-----------------|--------------|
| Case1  | 56  | Male   | II        | Ascending colon   | No                  | No                | No             | Capecitabine (single) | 37.5         |
| Case2  | 61  | Male   | II        | Ascending colon   | No                  | No                | No             | Capecitabine (single) | 26.8         |
| Case3  | 57  | Male   | II        | Ascending colon   | No                  | No                | No             | Capecitabine (single) | 41.3         |
| Case4  | 58  | Female | II        | Sigmoid colon     | No                  | No                | No             | Capecitabine (single) | 28.7         |
| Case5  | 55  | Male   | II        | Ascending colon   | No                  | No                | No             | Capecitabine (single) | 45.1         |
| Case6  | 55  | Male   | II        | Rectum           | No                  | No                | No             | Capecitabine (single) | 33.8         |
| Case7  | 52  | Female | II        | Rectum           | No                  | No                | No             | Capecitabine (single) | 32.7         |
| Case8  | 69  | Male   | II        | Rectum           | No                  | No                | No             | Capecitabine (single) | 35.6         |

has shown that ABCB4 modulates the doxorubicin resistance in ovarian cells [26] and the paclitaxel resistance in breast cancer cells [27]. Furthermore, caused by the hypermethylation of CpG promoter, ABCB4 is epigenetically silenced to initiate the tumor growth [28]. In the pediatric medulloblastoma, high expression of ABCB4 links to the radiation resistance [29]. Inspite of some controversies, ABCB4 is worthy of consideration as a target for illustrating the resistance in human cancers. In addition to the molecular researches, a population-based research showed lower transcript level of ABCB4 in accordance with a shorter disease-free interval in colorectal cancer patients treated by adjuvant chemotherapy [30]. However, the question of whether ABCB4 functions in CRC has not yet been explored.
Figure 4. ABCB4 is significantly associated with clinical prognosis

(A) ABCB4 was significantly down-regulated in the tumor tissues from TCGA(COADREAD) cohort; \( P<0.0001 \). (B) ABCB4 was down-regulated in the recurrent tissues compared with the first primary tumor. P-tumor represents the first primary tumor and R-tumor represents the corresponding recurrent tumor; \( P=0.039 \). (C) Kaplan–Meier curves showed that ABCB4 expression is significantly associated with a shorter recurrence-free survival in CRC patients; Log-rank \( P=0.01 \). (D) Kaplan–Meier curves showed that ABCB4 expression is significantly associated with a shorter overall survival in CRC patients; Log-rank \( P=0.03 \).

Table 3 Univariate and multivariate analysis of recurrence-related factors in CRC patients

| Variable                        | Univariate Hazard ratio (HR, 95%CI) | \( P \) | HR (95%CI) | \( P \) |
|---------------------------------|-------------------------------------|-------|------------|-------|
| Age                             | 0.998 (0.972–1.024)                 | 0.86  | 0.997 (0.966–1.028) | 0.840 |
| Gender                          |                                     |       |            |       |
| Male                            | 2.654 (1.273–5.534)                 | 0.007 | 3.605 (1.562–8.374) | 0.003 |
| Female                          | 1                                   |       | 1          |       |
| TNM stage                       |                                     |       |            |       |
| Early stage (stage I + stage II)| 0.481 (0.241 to 0.959)              | 0.038 | 0.384 (0.173–0.852) | 0.019 |
| Late stage (stage III + stage IV)| 1                                   |       | 1          |       |
| Perineural invasion             |                                     |       |            |       |
| YES                             | 1                                   |       | 1.180 (0.524–2.660) | 0.689 |
| NO                              | 0.824 (0.408–1.664)                 | 0.590 |            |       |
| Lymphatic invasion              |                                     |       |            |       |
| YES                             | 1                                   |       | 1.180 (0.524–2.660) | 0.689 |
| NO                              | 0.480 (0.237 to 0.973)              | 0.042 | 0.819 (0.292–2.300) | 0.705 |
| Venous invasion                 |                                     |       |            |       |
| YES                             | 1                                   |       | 1          |       |
| NO                              | 0.564 (0.275–1.158)                 | 0.119 | 0.888 (0.317–2.488) | 0.821 |
| ABCB4 expression                |                                     |       |            |       |
| High                            | 1                                   |       |            |       |
| Low                             | 2.142 (1.032–4.449)                 | 0.041 | 2.743 (1.291–5.827) | 0.01  |
In the present study, the relationship between ABCB4 and chemoresistance has been established and the insights of mechanism to implication of apoptosis induced by ABCB4 with 5-Fu treatment have also been described. We show that ABCB4 is down-regulated at the mRNA and protein level in the HCT8R cells. Knockdown of ABCB4 suppresses the caspase-dependent apoptosis pathway, which is canonical in regulating the resistance in cancer [31-33]. In order to verify the results, overexpression of ABCB4 in HCT8R cells has been performed. We have found that overexpression of the ABCB4 enhanced the sensitivity to 5-Fu and induced the apoptotic response in the HCT8R cells. All these data have shown that ABCB4 regulates the chemoresistance to 5-Fu in the HCT8 cells. Our data have some similarities with the published papers. A previous study provided evidence that loss of ABCB4 enhances the cell proliferation in many cancers [28]. In addition to the biological importance, we found that ABCB4 is down-regulated in the CRC and recurrent patients. Moreover, ABCB4 has an association with the risk of recurrence and overall survival, which is in accordance with a previous report [30]. Our works suggest that ABCB4 may serve as a predictor for recurrence after 5-Fu based chemotherapy in CRC patients. Thus, it may be important to classified the patients according to the ABCB4 expression to provide a more precise therapeutic strategy.

Although ABCB4 shares some similarity with ABCB1 [20], the ABCB4 showed a different pattern in the colorectal cancer. Inspite of high sequence identity with the ABCB1, ABCB4 had a transcript of 4100 nucleotides, 400 nucleotides less than the transcript of ABCB1 [20]. The N-terminal domain of ABCB4, different form other region, is not conserved with the ABCB1 and this region is important for the function of ABCB4, which had shown association with the LPAC syndrome and ICP [34]. The N-terminal of ABCB4 also has a phosphorylated site, which was involved in the substrate transportation [34]. As for the function in cancer, there some ABC members reported to be down-regulated such as ABCA7, ABCA12, ABCB2, ABCB5, and ABCD1 in the melanoma [35]. This suggests that pattern of lower expression in ABC family members may play a part in the cancer. ABCB4 has been found to be inactivated in many epithelial cancers including the lung, breast, and head and neck, which is due to the hypermethylation of the promoter [36-39]. The direct evidence have shown that loss of ABCB4 promotes the proliferation in the lung cancer [28]. These previous researches support the hypothesis that ABCB4 may function in cancers via inactivation.

We do acknowledge some limitations of our study. For instance, only one cell line is included, which cannot print a whole picture of cancer due to the heterogeneity and lack of the influence from the circumferential environments without in vivo assay. To set off these drawbacks, we validate the results acquired from cell line in three patient cohorts. Just as we planned, consistent outcomes have been observed in these cohorts.

In summary, we have ridicated a novel association of ABCB4 and chemoresistance in CRC. Our findings provide insights into the mechanism of ABCB4, as we have identified that ABCB4 induce apoptosis in CRC. Most of all, ABCB4 may act as a valuable clinical factor predicting the survival in CRC. Further investigations could gear toward understanding the effects of ABCB4 on chemoresistance in vivo.

Funding
This work has been financially supported by the National Natural Science Foundation of China (Grant number: 81572930) and Beijing Municipal Science & Technology Commission (No. Z16110000116090).

Author Contribution
Hanqing Hu, Xu Gao, and Xishan Wang conducted the research design. Hanqing Hu, Meng Wang, Xu Guan, and Chaoxia Zou performed all the molecular biological experiments. Hanqing Hu, Zheng Liu, Ziming Yuan, and Guiyu Wang collected all the samples from patients and carried out statistical analysis.

Competing Interests
The authors declare that there are no competing interests associated with the manuscript.

Abbreviations
5-Fu, 5-fluorouracil; ABC, adenosine triphosphate-binding cassette; ABCB1, ATP-binding cassette protein B1; ABCG2, ATP-binding cassette protein G2; COX, proportional hazards model; CRC, colorectal cancer; FITC, fluorescein isothiocyanate; HCT8, human colon cancer cell line; HCT8R, HCT8 5-Fu resistant cell line; HCT8S, HCT8 5-Fu sensitive cell line; HR, hazard ratio; HRP, horseradish peroxidase; IC50, 50% inhibitory concentration; ICP, Intra-tal cancer; FITC, fluorescein isothiocyanate; HCT8, human colon cancer cell line; HCT8R, HCT8 5-Fu resistant cell line; HCT8S, ATP-binding cassette protein C2; ABCG2, ATP-binding cassette protein G2; COX, proportional hazards model; CRC, colorectal cancer; FITC, fluorescein isothiocyanate; HCT8, human colon cancer cell line; HCT8R, HCT8 5-Fu resistant cell line; HCT8S,
Criteria in Solid Tumors; RFS, recurrence-free survival; SDS, sodium dodecyl sulfate; siRNA, small interfering RNA; TCGA, the cancer genome atlas; TNM, TNM staging system.

References
1 Siegel, R.L., Miller, K.D. and Jemal, A. (2017) Cancer Statistics, 2017. CA Cancer J. Clin. 67, 7–30, https://doi.org/10.3322/caac.21387
2 Markowitz, S.D. and Bertagnolli, M.M. (2009) Molecular origins of cancer: Molecular basis of colorectal cancer. N. Engl. J. Med. 361, 2449–2460, https://doi.org/10.1056/NEJMra0804588
3 Giaccetti, S., Perpoint, B., Zidani, R., Le Bail, N., Faggiuolo, R., Focan, C. et al. (2000) Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J. Clin. Oncol. 18, 136–147, https://doi.org/10.1200/JCO.2000.18.1.136
4 Douillard, J.Y., Cunningham, D., Roth, A.D., Navarro, M., James, R.D., Karasek, P. et al. (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355, 1041–1047, https://doi.org/10.1016/S0140-6736(00)02034-1
5 Islam, Z., Strutztenberg, T.S., Gurevic, I. and Kohen, A. (2014) Concerted versus stepwise mechanism in thymidylate synthase. J. Am. Chem. Soc. 136, 9850–9853, https://doi.org/10.1021/ja504341g
6 Ween, M.P., Armstrong, M.A., Oehler, M.K. and Ricciardelli, C. (2015) The role of ABC transporters in ovarian cancer progression and chemoresistance. Crit. Rev. Oncol. Hematol. 96, 220–256, https://doi.org/10.1016/j.critrevonc.2015.05.012
7 Morrissey, K.M., Wen, C.C., Johns, S.J., Zhang, L., Huang, S.M. and Giacomini, K.M. (2012) The UCSF-FDA TransPortal: a public drug transporter database. Clin. Pharmacol. Ther. 92, 545–546, https://doi.org/10.1038/cpt.2012.44
8 Zhou, S.F. (2008) Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition. Xenobiotica 38, 802–832, https://doi.org/10.1080/00498250701867889
9 Sharam, F.J. (2008) ABC multidrug transporters: structure, function and role in chemoresistance. Pharmacogenomics 9, 105–127, https://doi.org/10.2217/14622416.9.1.105
10 Borst, P., Evers, R., Kool, M. and Wijnholds, J. (2000) A family of drug transporters: the multidrug resistance-associated proteins. J. Natl. Cancer Inst. 92, 1295–1302, https://doi.org/10.1093/jnci/92.16.1295
11 Jelditschky, G., Hoffmann, U. and Kroemer, H.K. (2006) Structure and function of the MRP2 (ABCC2) protein and its role in drug disposition. Expert Opin. Drug Metab. Toxicol. 2, 351–366, https://doi.org/10.1517/17425255.2.3.351
12 Zhou, S.F., Wang, L.L., Di, Y.M., Xue, C.C., Duan, W., Li, C.G. et al. (2008) Substrates and inhibitors of human multidrug resistance associated proteins and the implications in drug development. Curr. Med. Chem. 15, 1981–2039, https://doi.org/10.2174/092986708785132870
13 Slot, A.J., Molinski, S.V. and Cole, S.P. (2011) Mammalian multidrug-resistance proteins (MRPs). Essays Biochem. 50, 179–207, https://doi.org/10.1042/ese0500179
14 Konig, J., Muller, F. and Fromm, M.F. (2013) Transporters and drug-drug interactions: important determinants of drug disposition and effects. Pharmacol. Rev. 65, 944–966, https://doi.org/10.1124/pr.113.007518
15 Mao, Q. and Undakat, J.D. (2015) Role of the breast cancer resistance protein (BCRP/ABC22) in drug transport–an update. AAPS J. 17, 65–82, https://doi.org/10.1208/s12248-014-9666-6
16 Smit, J.J., Schinkel, A.H., Oude Elferink, R.P., Groen, A.K., Wagenaar, E., van Deemter, L. et al. (1993) Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell 75, 451–462, https://doi.org/10.1016/0092-8674(93)90380-9
17 Rütz, S. and Gros, P. (1994) Phosphatidylcholine translocase: a physiological role for the mdr2 gene. Cell 77, 1071–1081, https://doi.org/10.1016/0092-8674(94)90446-4
18 Wang, D.Q., Cohen, D.E. and Carey, M.C. (2009) Biliary lipids and cholesterol gallstone disease. J. Lipid Res. 50, S406–S411, https://doi.org/10.1194/jlr.R800075-JLR200
19 Borst, P., Zelcer, N. and van Helvoort, A. (2000) ABC transporters in lipid transport. Biochim. Biophys. Acta 1486, 128–144, https://doi.org/10.1016/S0005-2760(00)001449-6
20 Van der Bliek, A.M., Baas, F., Ten Houte de Lange, T., Kooiman, P.M., Van der Velde-Koerts, T. and Borst, P. (1987) The human mdr3 gene encodes a novel P-glycoprotein homologue and gives rise to alternatively spliced mRNAs in liver. EMBO J. 6, 3325–3331
21 Zolnerciks, J.K., Andress, E.J., Nicolaou, M. and Linton, K.J. (2011) Structure of ABC transporters. J. Biol. Chem. 286, 168–174, https://doi.org/10.1074/jbc.M110.129564
22 Xiong, H., Hong, J., Du, W., Lin, Y.W., Ren, L.L., Wang, Y.C. et al. (2012) Roles of STAT3 and ZEB1 proteins in E-cadherin down-regulation and human colorectal cancer epithelial-mesenchymal transition. J. Biol. Chem. 287, 5819–5832, https://doi.org/10.1074/jbc.M111.295664
23 Sun, T.T., Tang, J.Y., Du, W., Zhao, H.J., Zhao, G., Yang, S.L. et al. (2015) Bidirectional regulation between TMEFF2 and STAT3 may contribute to Helicobacter pylori-associated gastric carcinogenesis. Int. J. Cancer 136, 1053–1064, https://doi.org/10.1002/ijc.29061
24 Januchowski, R., Sterzyńska, K., Zawierucha, P., Rucinski, M., Świerczewska, M., Partyka, M. et al. (2017) Microarray-based detection and expression analysis of new genes associated with drug resistance in ovarian cancer cell lines. Oncotarget 8, 49944–49958, https://doi.org/10.18632/oncotarget.18278
27 Nemcova-Furstova, V., Kopperova, D., Balusikova, K., Ehrlichova, M., Brynychova, V., Vaclavikova, R. et al. (2016) Characterization of acquired paclitaxel resistance of breast cancer cells and involvement of ABC transporters. *Toxicol. Appl. Pharmacol.* **310**, 215–228, https://doi.org/10.1016/j.taap.2016.09.020

28 Kiehl, S., Herkt, S.C., Richter, A.M., Fuhrmann, L., El-Nikhely, N., Seeger, W. et al. (2014) ABCB4 is frequently epigenetically silenced in human cancers and inhibits tumor growth. *Sci. Rep.* **4**, 6899, https://doi.org/10.1038/srep06899

29 Ingram, W.J., Crowther, L.M., Little, E.B., Freeman, R., Harliwong, I., Veleva, D. et al. (2013) ABC transporter activity linked to radiation resistance and molecular subtype in pediatric medulloblastoma. *Exp. Hematol Oncol.* **2**, 26, https://doi.org/10.1186/2162-3619-2-26

30 Hlavata, I., Mohelnikova-Duchonova, B., Vaclavikova, R., Liska, V., Phute, P., Novak, P. et al. (2012) The role of ABC transporters in progression and clinical outcome of colorectal cancer. *Mutagenesis* **27**, 187–196, https://doi.org/10.1039/mutage/ger075

31 Soengas, M.S. and Lowe, S.W. (2003) Apoptosis and melanoma chemoresistance. *Oncogene* **22**, 3138–3151, https://doi.org/10.1038/sj.onc.1206454

32 Schmitt, C.A. and Lowe, S.W. (2002) Apoptosis and chemoresistance in transgenic cancer models. *J. Mol. Med. (Berl.)* **80**, 137–146, https://doi.org/10.1007/s00109-001-0233-3

33 Kashkar, H. (2010) X-linked inhibitor of apoptosis: a chemoresistance factor or a hollow promise. *Clin. Cancer Res.* **16**, 4496–4502, https://doi.org/10.1158/1078-0432.CCR-10-1664

34 Gautherot, J., Delautier, D., Maubert, M.A., Ait-Slimane, T., Bolbach, G., Delaunay, J.L. et al. (2014) Phosphorylation of ABCB4 impacts its function: insights from disease-causing mutations. *Hepatology* **60**, 610–621, https://doi.org/10.1002/hep.27170

35 Heimerl, S., Bosserhoff, A.K., Langmann, T., Ecker, J. and Schmitz, G. (2007) Mapping ATP-binding cassette transporter gene expression profiles in melanocytes and melanoma cells. *Melanoma Res.* **17**, 265–273, https://doi.org/10.1097/CMR.0b013e3282a7e0b9

36 Bebek, G., Bennett, K.L., Funchain, P., Campbell, R., Seth, R., Scharpf, J. et al. (2012) Microbiomic subprofiles and MDR1 promoter methylation in head and neck squamous cell carcinoma. *Hum. Mol. Genet.* **21**, 1557–1565, https://doi.org/10.1093/hmg/ddr593

37 Sharma, D. and Vertino, P.M. (2004) Epigenetic regulation of MDR1 gene in breast cancer: CpG methylation status dominates the stable maintenance of a silent gene. *Cancer Biol. Ther.* **3**, 549–550, https://doi.org/10.4161/cbt.3.6.1041

38 Oberstadt, M.C., Bien-Moller, S., Weitmann, K., Herzog, S., Hentschel, K., Rimmbach, C. et al. (2013) Epigenetic modulation of the drug resistance genes MGMT, ABCB1 and ABCG2 in glioblastoma multiforme. *BMC Cancer* **13**, 617, https://doi.org/10.1186/1471-2407-13-617

39 Muggerud, A.A., Ronneberg, J.A., Warnberg, F., Botling, J., Busato, F., Jovanovic, J. et al. (2010) Frequent aberrant DNA methylation of ABCB1, FOXC1, PPP2R2B and PTEN in ductal carcinoma in situ and early invasive breast cancer. *Breast Cancer Res.* **12**, R3, https://doi.org/10.1186/bcr2466